MAP2K1 and cutaneous squamous cell carcinoma: Concomitant alterations in the MAP2K1 and FGFR3 genes, as it is in the present case, have been described in cases of cutaneous squamous cell carcinoma that presented a significant response to EGFR inhibitors (cetuximab) [36,38].